Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00792636 · ClinicalTrials.gov registry record · Phase 4

A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period

A Phase 4 study of Migraine Disorders, sponsored by GlaxoSmithKline.

Completed
Registry status
Phase 4
Development phase
407
Enrollment target
20
Study locations

NCT00792636 is a Phase 4 study of Migraine Disorders that has completed, run by GlaxoSmithKline. The registered enrollment target is 407 participants, above the 296-participant average among 21 other Migraine Disorders trials with a reported enrollment target (38% higher). The trial reports 20 study locations across 6 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00792636, a Phase 4 study of Migraine Disorders, has completed, sponsored by GlaxoSmithKline.

COMPLETED
Registry status
Phase 4
Development phase
407 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.

Conditions Studied

Migraine Disorders

Interventions

  • DRUG sumatriptan and naproxen sodium combination tablet
  • DRUG sumatriptan tablet
  • DRUG naproxen sodium tablet

Study Locations (20)

California

  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Anaheim
  • GSK Investigational Site - Buena Park
  • GSK Investigational Site - Garden Grove
  • GSK Investigational Site - Newport Beach
  • GSK Investigational Site - Santa Monica
  • GSK Investigational Site - Westlake Village

Arizona

  • GSK Investigational Site - Chandler
  • GSK Investigational Site - Gilbert
  • GSK Investigational Site - Litchfield Park
  • GSK Investigational Site - Phoenix
  • GSK Investigational Site - Tempe

Florida

  • GSK Investigational Site - Hialeah
  • GSK Investigational Site - Jacksonville
  • GSK Investigational Site - Miami
  • GSK Investigational Site - Pembroke Pines
  • GSK Investigational Site - St. Petersburg

Arkansas

  • GSK Investigational Site - Little Rock

Colorado

  • GSK Investigational Site - Colorado Springs

Connecticut

  • GSK Investigational Site - Avon

Trial Details

FieldValue
Enrollment Target 407 participants
Start Date 2008-11
Est. Completion 2009-11
Phase Phase 4

Sponsor

GlaxoSmithKline

1,345 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00792636

The ClinicalTrials.gov registry entry for NCT00792636 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 407 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 296-participant average among 21 other Migraine Disorders trials with a reported enrollment target (38% higher). The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Migraine Disorders appearing as the primary indexed condition, and to 3 interventions - of which sumatriptan and naproxen sodium combination tablet is the first listed.

NCT00792636 reports 20 study locations spanning 6 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT00792636 about?

NCT00792636 is a clinical study titled "A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period". The purpose of this study is to test the effect on blood pressure of sumatriptan and naproxen sodium combination tablets, tablets containing only sumatriptan, and tablets containing only naproxen sodium when these drugs are taken to treat migraine headaches that occur during a 6-month period.

What is the current status of trial NCT00792636?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 407 participants. The study started on 2008-11. Estimated completion is 2009-11.

What conditions does trial NCT00792636 study?

This clinical trial studies the following conditions: Migraine Disorders.

What interventions are being tested in trial NCT00792636?

The interventions under investigation include: sumatriptan and naproxen sodium combination tablet (DRUG), sumatriptan tablet (DRUG), naproxen sodium tablet (DRUG).

Who is sponsoring clinical trial NCT00792636?

This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00792636 being conducted?

This trial has 20 study locations across Arizona, Arkansas, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Migraine Disorders

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Migraine Disorders

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.